311 related articles for article (PubMed ID: 26316061)
1. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.
Hernández-Flórez D; Valor L; de la Torre I; Nieto JC; Martínez-Estupiñán L; González C; López-Longo FJ; Monteagudo I; Garrido J; Naredo E; Carreño L
Rheumatol Int; 2015 Jun; 35(6):1021-5. PubMed ID: 25410014
[TBL] [Abstract][Full Text] [Related]
3. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
4. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
5. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
Martínez-Estupiñán L; Hernández-Flórez D; Janta I; Ovalles-Bonilla JG; Nieto JC; González-Fernández CM; Del Río T; Monteagudo I; López-Longo FJ; Naredo E; Valor L
Clin Exp Rheumatol; 2018; 36(1):88-93. PubMed ID: 28850020
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Marín-Jiménez I; Menchén LA; López-Cauce B; López-Fernández LA; Lucendo AJ
J Pharm Biomed Anal; 2021 May; 198():114003. PubMed ID: 33714800
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
[TBL] [Abstract][Full Text] [Related]
10. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
Siljehult F; Ärlestig L; Eriksson C; Rantapää-Dahlqvist S
Scand J Rheumatol; 2018 Sep; 47(5):345-350. PubMed ID: 29701536
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice.
Rosas J; Llinares-Tello F; de la Torre I; Santos-Ramírez C; Senabre-Gallego JM; Valor L; Barber-Vallés X; Hernández-Flórez D; Santos-Soler G; Salas-Heredia E; Carreño L;
Clin Exp Rheumatol; 2014; 32(6):942-8. PubMed ID: 25327159
[TBL] [Abstract][Full Text] [Related]
13. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
[TBL] [Abstract][Full Text] [Related]
14. Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis.
Martínez-Feito A; Plasencia-Rodríguez C; Novella-Navarro M; Gehin JE; Hernández-Breijo B; Brenis CM; Villalba-Yllán A; Fernández E; Monjo-Henry I; Pascual-Salcedo D; Nozal P; Balsa A
Clin Exp Rheumatol; 2024 May; 42(5):999-1005. PubMed ID: 38197184
[TBL] [Abstract][Full Text] [Related]
15. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.
Ogrič M; Terčelj M; Praprotnik S; Tomšič M; Božič B; Sodin-Semrl S; Čučnik S
Immunol Res; 2017 Feb; 65(1):172-185. PubMed ID: 27421721
[TBL] [Abstract][Full Text] [Related]
16. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
17. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
Rissel F; Cazaubon Y; Saffar S; Altwegg R; Artasone M; Lozano C; Vincent T; Jentzer A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373525
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
[TBL] [Abstract][Full Text] [Related]
20. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
